Registries as a source of RWE

Registries as a source of RWE - Stella Blackburn

11:00 AM - 11:35 AM

In the past, clinical trials were seen as the only way of providing valid evidence for a marketing authorisation of a product. Real world evidence was traditionally viewed as being primarily of use in the post-marketing setting. However, registries, when used appropriately, are a valuable resource which can speed up drug development at different stages in the product life-span. This presentation will cover:

• Definition of a registry
• Different types of registries
• Uses of registries throughout the product life-span
• Situations where registries are probably essential
• EMA’s registry initiatives